Text Size

Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease – a randomized controlled trial

Konstas A.-G., Boboridis K. G., Athanasopoulos G. P., Haidich A.-B., Voudouragkaki I. C., Pagkalidou E., Katsanos A., Katz L. J.

  • 2023
  • Eye
View publication
  • Therapeutic Area


  • Categories

    Clinical development

  • Affiliations

    University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Epidemiology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Ophthalmology, University of Ioannina, Ioannina, Greec; Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA

Related Publications

24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.

Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022